TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Trump Says Anthropic No Longer Seen as National Security Threat 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
VANCOUVER, British Columbia, Jan. 27, 2016 -- AbCellera, a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced a new collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to generate antibodies against an undisclosed disease target.
“Our platform has the potential to generate functional antibodies against extremely difficult targets that have been intractable until now,” says Dr. Carl Hansen, President and CEO of AbCellera. “We’re excited to partner with a global innovator like Merck in the discovery of antibodies to advance their pipeline of next-generation therapies.”
“Merck recognizes the innovative science and synergy of collaboration in British Columbia. Our company has established several life sciences collaborations in the province aimed at translating breakthrough science into products that can bring meaningful improvements to patients' lives,” explained Chirfi Guindo, President and Managing Director at Merck Canada Inc. “We are pleased to be working with AbCellera to identify novel antibodies using their innovative microfluidic discovery technology.”
Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function. The agreement grants Merck the option to develop antibody candidates identified through the collaboration for specified therapeutic applications. Financial terms of the deal were not disclosed.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans. For more information, please visit www.abcellera.com
Contact Kevin Heyries Telephone: 604.827.4151 Email: [email protected]
